Journal
CANCER TREATMENT REVIEWS
Volume 42, Issue -, Pages 30-40Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2015.11.008
Keywords
Cervical cancer; Radiotherapy; Cisplatin; DNA damage response; DDR-inhibitors
Categories
Funding
- Dutch Cancer Society [RUG/NKB 2010-4833]
- Netherlands Organization for Scientific Research [NWO-VIDI 016.136.334]
- Junior Scientific Master class (JSM) of the University of Groningen
Ask authors/readers for more resources
Every year, cervical cancer affects similar to 500,000 women worldwide, and similar to 275,000 patients die of this disease. The addition of platin-based chemotherapy to primary radiotherapy has increased 5-year survival of advanced-stage cervical cancer patients, which is, however, still only 66%. One of the factors thought to contribute to treatment failure is the ability of tumor cells to repair chemoradiotherapy-induced DNA damage. Therefore, sensitization of tumor cells for chemoradiotherapy via inhibition of the DNA damage response (DDR) as a novel strategy to improve therapy effect, is currently studied pre-clinically as well as in the clinic. Almost invariably, cervical carcinogenesis involves infection with the human papillomavirus (HPV), which inactivates part of the DNA damage response. This HPV-mediated partial inactivation of the DDR presents therapeutic targeting of the residual DDR as an interesting approach to achieve chemoradio-sensitization for cervical cancer. How the DDR can be most efficiently targeted, however, remains unclear. The fact that cisplatin and radiotherapy activate multiple signaling axes within the DDR further complicates a rational choice of therapeutic targets within the DDR. In this review, we provide an overview of the current preclinical and clinical knowledge about targeting the DDR in cervical cancer. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available